<?xml version="1.0" encoding="us-ascii"?><InstanceReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><Version>2.4.0.8</Version><ReportLongName>107 - Disclosure - Summary of Significant Accounting Policies</ReportLongName><DisplayLabelColumn>true</DisplayLabelColumn><ShowElementNames>false</ShowElementNames><RoundingOption /><HasEmbeddedReports>false</HasEmbeddedReports><Columns><Column FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><CurrencyCode /><FootnoteIndexer /><hasSegments>false</hasSegments><hasScenarios>false</hasScenarios><MCU><KeyName /><CurrencySymbol /><contextRef><ContextID>eol_PE11233---1310-Q0008_STD_181_20130630_0</ContextID><EntitySchema>http://www.sec.gov/CIK</EntitySchema><EntityValue>0001020214</EntityValue><PeriodDisplayName /><PeriodType>duration</PeriodType><PeriodStartDate>2013-01-01T00:00:00</PeriodStartDate><PeriodEndDate>2013-06-30T00:00:00</PeriodEndDate><Segments /><Scenarios /></contextRef><UPS /><CurrencyCode /><OriginalCurrencyCode /></MCU><CurrencySymbol /><Labels><Label Key="CalendarSupplement" Id="0" Label="6 Months Ended" /><Label Key="Calendar" Id="1" Label="Jun. 30, 2013" /></Labels></Column></Columns><Rows><Row FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>4</Level><ElementName>us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</ElementName><ElementPrefix>us-gaap_</ElementPrefix><IsBaseElement>true</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><PreferredLabelRole>terseLabel</PreferredLabelRole><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="eol_PE11233---1310-Q0008_STD_181_20130630_0" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText>&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note 1. Summary of
Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Principles of
Consolidation and Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
accompanying unaudited condensed consolidated financial statements
include those of Cerus Corporation and its subsidiary, Cerus Europe
B.V. (collectively referred to hereinafter as &amp;#x201C;Cerus&amp;#x201D;
or the &amp;#x201C;Company&amp;#x201D;) after elimination of all intercompany
accounts and transactions. These condensed consolidated financial
statements have been prepared in accordance with accounting
principles generally accepted in the United States of America
(&amp;#x201C;GAAP&amp;#x201D;) for interim financial information and pursuant
to the rules and regulations of the Securities and Exchange
Commission (&amp;#x201C;SEC&amp;#x201D;). Accordingly, they do not include
all of the information and footnotes required by GAAP for complete
financial statements. In the opinion of management, all
adjustments, consisting of normal recurring entries, considered
necessary for a fair presentation have been made. Operating results
for the three and six months ended June&amp;#xA0;30, 2013, are not
necessarily indicative of the results that may be expected for the
year ending December&amp;#xA0;31, 2013, or for any future
periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;These condensed
consolidated financial statements and notes thereto should be read
in conjunction with the Company&amp;#x2019;s audited financial
statements and notes thereto for the year ended December&amp;#xA0;31,
2012, which were included in the Company&amp;#x2019;s 2012 Annual Report
on Form 10-K, filed with the SEC on March&amp;#xA0;12, 2013. The
accompanying balance sheet as of December&amp;#xA0;31, 2012, has been
derived from the Company&amp;#x2019;s audited financial statements as of
that date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Use of
Estimates&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The preparation
of financial statements requires management to make estimates,
assumptions and judgments that affect the reported amounts of
assets, liabilities, revenue and expenses, and related disclosures
of contingent assets and liabilities. On an ongoing basis,
management evaluates its estimates, which are based on historical
experience and on various other assumptions that are believed to be
reasonable under the circumstances. Actual results may differ from
those estimates under different assumptions or
conditions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Revenue&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
recognizes revenue in accordance with ASC Topic 605-25,
&lt;i&gt;&amp;#x201C;Revenue Recognition &amp;#x2013; Arrangements with Multiple
Deliverables,&amp;#x201D;&lt;/i&gt; as applicable. Revenue is recognized when
(i)&amp;#xA0;persuasive evidence of an agreement with the funding party
exists; (ii)&amp;#xA0;services have been rendered or product has been
delivered; (iii)&amp;#xA0;pricing is fixed or determinable; and
(iv)&amp;#xA0;collection is reasonably assured. The Company&amp;#x2019;s
main sources of revenues for the three and six months ended
June&amp;#xA0;30, 2013, and 2012, were product revenue from sales of
the INTERCEPT Blood System for platelets and plasma
(&amp;#x201C;platelet and plasma systems&amp;#x201D;) and United States
government grants and awards.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Revenue related
to product sales is generally recognized when the Company fulfills
its obligations for each element of an agreement. For all sales of
the Company&amp;#x2019;s INTERCEPT Blood System products, the Company
uses a binding purchase order and signed sales contract as evidence
of a written agreement. The Company sells its platelet and plasma
systems directly to blood banks, hospitals, universities,
government agencies, as well as to distributors in certain regions.
Generally, the Company&amp;#x2019;s contracts with its customers do not
provide for open return rights, except within a reasonable time
after receipt of goods in the case of defective or non-conforming
product. Deliverables and the units of accounting vary according to
the provisions of each purchase order or sales contract. For
revenue arrangements with multiple elements, the Company determines
whether the delivered elements meet the criteria as separate units
of accounting. Such criteria require that the deliverable have
stand-alone value to the customer and that if a general right of
return exists relative to the delivered item, delivery or
performance of the undelivered item(s) is considered probable and
substantially in the control of the Company. Once the Company
determines if the deliverable meets the criteria for a separate
unit of accounting, the Company must determine how the
consideration should be allocated between the deliverables and how
the separate units of accounting should be recognized as revenue.
Consideration received is allocated to elements that are identified
as discrete units of accounting based on the best estimated selling
price. The Company has determined that vendor specific objective
evidence is not discernible due to the Company&amp;#x2019;s limited
history of selling its products and variability in its pricing
across the regions into which it sells its products. Since the
Company&amp;#x2019;s products are novel and unique and are not sold by
others, third-party evidence of selling price is
unavailable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At
June&amp;#xA0;30, 2013, and December&amp;#xA0;31, 2012, the Company had $
0.2&amp;#xA0;million and $0.1 million, respectively, of short-term
deferred revenue on its condensed consolidated balance sheets
related to future performance obligations. Freight costs charged to
customers are recorded as a component of revenue under ASC Topic
605, &lt;i&gt;&amp;#x201C;Accounting for Shipping and Handling Fees and
Costs.&amp;#x201D;&lt;/i&gt; Value-added-taxes (&amp;#x201C;VAT&amp;#x201D;) that the
Company invoices to its customers and remits to governments are
recorded on a net basis, which excludes such VAT from product
revenue.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Revenue related
to the cost reimbursement provisions under development contracts or
United States government grants is recognized as the costs on the
projects are incurred. The Company has received certain United
States government grants and contracts that support research in
defined research projects. These grants generally have provided for
reimbursement of approved costs incurred as defined in the various
grants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Research and Development
Expenses&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In accordance
with ASC Topic 730, &lt;i&gt;&amp;#x201C;Accounting for Research and
Development Expenses,&amp;#x201D;&lt;/i&gt; research and development expenses
are charged to expense when incurred, including cost incurred under
each grant that has been awarded to the Company by the United
States government or development contracts. Research and
development expenses include salaries and related expenses for
scientific personnel, payments to consultants, supplies and
chemicals used in in-house laboratories, costs of research and
development facilities, depreciation of equipment and external
contract research expenses, including clinical trials, preclinical
safety studies, other laboratory studies, process development and
product manufacturing for research use.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
Company&amp;#x2019;s use of estimates in recording accrued liabilities
for research and development activities (see &amp;#x201C;Use of
Estimates&amp;#x201D; above) affects the amounts of research and
development expenses recorded and revenue recorded from development
funding and government grants and collaborative agreements. Actual
results may differ from those estimates under different assumptions
or conditions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Cash
Equivalents&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
considers all highly liquid investments with original maturities of
three months or less from the date of purchase to be classified as
cash equivalents. These investments primarily consist of money
market instruments, and are classified as
available-for-sale.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Short-Term
Investments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Investments
with original maturities of greater than three months but less than
one year from the date of purchase as well as available-for-sale
investments with original maturities of greater than one year from
the date of purchase, which included United States government
agency securities, are classified as short-term investments. In
accordance with ASC Topic 320, &lt;i&gt;&amp;#x201C;Accounting for Certain
Investments in Debt and Equity Securities,&amp;#x201D;&lt;/i&gt; the Company
has classified all debt securities as available-for-sale at the
time of purchase and reevaluates such designation as of each
balance sheet date. Available-for-sale securities are carried at
estimated fair value. Unrealized gains and losses derived by
changes in the estimated fair value of available-for-sale
securities are recorded in &amp;#x201C;Accumulated other comprehensive
income&amp;#x201D; on the Company&amp;#x2019;s condensed consolidated balance
sheets and/or in &amp;#x201C;Net unrealized losses on available-for-sale
securities, net of taxes&amp;#x201D; on the Company&amp;#x2019;s condensed
consolidated statements of comprehensive loss. Realized gains and
losses from the sale or maturity of available-for-sale investments
are recorded in &amp;#x201C;Other income, net&amp;#x201D; on the
Company&amp;#x2019;s condensed consolidated statements of operations.
The cost of securities sold is based on the specific identification
method. The Company reports the amortization of any premium and
accretion of any discount resulting from the purchase of debt
securities as a component of interest expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
also reviews all of its marketable securities on a regular basis to
evaluate whether any security has experienced an
other-than-temporary decline in fair value. Other-than-temporary
declines in market value are recorded in &amp;#x201C;Other income
(expense), net&amp;#x201D; on the Company&amp;#x2019;s condensed consolidated
statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Restricted
Cash&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
holds a certificate of deposit with a domestic bank for any
potential decommissioning resulting from the Company&amp;#x2019;s
possession of radioactive material. The certificate of deposit is
held to satisfy the financial surety requirements of the California
Department of Health Services and is recorded in &amp;#x201C;Restricted
cash&amp;#x201D; on the Company&amp;#x2019;s condensed consolidated balance
sheets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Concentration of Credit
Risk&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Financial
instruments that potentially subject the Company to concentrations
of credit risk consist primarily of cash equivalents, short-term
investments and accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Pursuant to the
Company&amp;#x2019;s investment policy, substantially all of the
Company&amp;#x2019;s cash, cash equivalents and short-term investments
are maintained at a major financial institution of high credit
standing. The Company monitors the financial credit worthiness of
the issuers of its investments and limits the concentration in
individual securities and types of investments that exist within
its investment portfolio. Generally, all of the Company&amp;#x2019;s
investments carry high credit quality ratings, which is in
accordance with its investment policy. At June&amp;#xA0;30, 2013, the
Company does not believe there is significant financial risk from
non-performance by the issuers of the Company&amp;#x2019;s cash
equivalents.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Concentrations
of credit risk with respect to trade receivables exist. However, in
connection with the Company&amp;#x2019;s revolving line of credit, as
discussed in Note 8 in the Notes to Condensed Consolidated
Financial Statements, the Company purchased a credit insurance
policy that mitigates some of its credit risk, as the policy will
pay either the Company or its lender on eligible claims filed on
its outstanding receivables. On a regular basis, including at the
time of sale, the Company performs credit evaluations of its
customers. Generally, the Company does not require collateral from
its customers to secure accounts receivable. To the extent that the
Company determines specific invoices or customer accounts may be
uncollectible, the Company reserves against the accounts receivable
on its condensed consolidated balance sheets and records a charge
on its condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company had
four customers and three customers that accounted for more than 10%
of the Company&amp;#x2019;s outstanding trade receivables at both
June&amp;#xA0;30, 2013, and December&amp;#xA0;31, 2012. These customers
cumulatively represented approximately 64&amp;#xA0;% and 59% of the
Company&amp;#x2019;s outstanding trade receivables, at June&amp;#xA0;30,
2013, and December&amp;#xA0;31, 2012, respectively. To date, the
Company has not experienced collection difficulties from these
customers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;At
June&amp;#xA0;30, 2013, and December&amp;#xA0;31, 2012, inventory consisted
of work-in-process and finished goods only. Finished goods include
INTERCEPT disposable kits, UVA illumination devices
(&amp;#x201C;illuminators&amp;#x201D;), and certain replacement parts for the
illuminators. Platelet and plasma systems&amp;#x2019; disposable kits
generally have a two-year life from the date of manufacture.
Illuminators and replacement parts do not have regulated expiration
dates. Work-in-process includes certain components that are
manufactured over a protracted length of time, which can exceed one
year, before being incorporated and assembled by Fresenius, Inc.
(&amp;#x201C;Fresenius&amp;#x201D;) into the finished INTERCEPT disposable
kits. The Company maintains an inventory balance based on its
current sales projections, and at each reporting period, the
Company evaluates whether its work-in-process inventory would be
consumed for production of finished units in order to sell to
existing and prospective customers within the next twelve-month
period. It is not customary for the Company&amp;#x2019;s production
cycle for inventory to exceed twelve months. Instead, the Company
uses its best judgment to factor in lead times for the production
of its finished units to meet the Company&amp;#x2019;s current demands.
If actual results differ from those estimates, work-in-process
inventory could potentially accumulate for periods exceeding one
year. At June&amp;#xA0;30, 2013, and December&amp;#xA0;31, 2012, the
Company classified its work-in-process inventory as a current asset
on its condensed consolidated balance sheets based on its
evaluation that the work-in-process inventory would be consumed for
production and subsequently sold within each respective subsequent
twelve-month period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Inventory is
recorded at the lower of cost, determined on a first-in, first-out
basis, or market value. The Company uses significant judgment to
analyze and determine if the composition of its inventory is
obsolete, slow-moving or unsalable and frequently reviews such
determinations. The Company&amp;#x2019;s limited history selling the
INTERCEPT Blood System limits the amount of historical data the
Company has to perform this analysis. Generally, the Company
writes-down specifically identified unusable, obsolete,
slow-moving, or known unsalable inventory that has no alternative
use in the period that it is first recognized by using a number of
factors including product expiration dates, open and unfulfilled
orders, and sales forecasts. Any write-down of its inventory to net
realizable value establishes a new cost basis and will be
maintained even if certain circumstances suggest that the inventory
is recoverable in subsequent periods. Costs associated with the
write-down of inventory are recorded in &amp;#x201C;Cost of product
revenue&amp;#x201D; on the Company&amp;#x2019;s condensed consolidated
statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Property and Equipment,
net&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Property and
equipment is comprised of furniture, equipment, information
technology hardware and software and is recorded at cost. At the
time the property and equipment is ready for its intended use, it
is depreciated on a straight-line basis over the estimated useful
lives of the assets (generally three to five years). Leasehold
improvements are amortized on a straight-line basis over the
shorter of the lease term or the estimated useful lives of the
improvements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Goodwill and Intangible
Assets, net&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Additions to
goodwill and intangible assets, net are derived at the time of a
business acquisition, in which the Company assigns the total
consideration transferred to the acquired assets based on each
asset&amp;#x2019;s fair value and any residual amount becomes goodwill,
an indefinite life intangible asset. Intangible assets, net, which
include a license for the right to commercialize the INTERCEPT
Blood System in Asia, are subject to ratably amortized over the
estimated useful life of ten years. The amortization of the
Company&amp;#x2019;s intangible assets, net, is recorded in
&amp;#x201C;Amortization of intangible assets&amp;#x201D; on the
Company&amp;#x2019;s condensed consolidated statements of
operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Goodwill is not
amortized but instead is subject to an impairment test performed on
an annual basis, or more frequently if events or changes in
circumstances indicate that goodwill may be impaired. The Company
evaluates goodwill on an annual basis on August&amp;#xA0;31 of each
fiscal year. The test for goodwill impairment is a two-step
process. The first step compares the fair value of each reporting
unit with its respective carrying amount, including goodwill. The
Company has determined that it operates in one reporting unit and
estimates the fair value of its one reporting unit using the
enterprise approach under which it considers the quoted market
capitalization of the Company as reported on the Nasdaq Global
Market. The Company considers quoted market prices that are
available in active markets to be the best evidence of fair value.
The Company also considers other factors, which include future
forecasted results, the economic environment and overall market
conditions. If the fair value of the reporting unit exceeds its
carrying amount, goodwill of the reporting unit is not considered
impaired and, therefore, the second step of the impairment test is
unnecessary. The second step, which is used to measure the amount
of impairment loss, compares the implied fair value of each
reporting unit&amp;#x2019;s goodwill with the respective carrying amount
of that goodwill. If the carrying amount of the reporting
unit&amp;#x2019;s goodwill exceeds the implied fair value of that
goodwill, an impairment loss is recognized in an amount equal to
that excess.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See Note 5 in
the Notes to Condensed Consolidated Financial Statements for
further information regarding the Company&amp;#x2019;s impairment
analysis and the valuation of goodwill and intangible assets,
net.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Long-lived
Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
evaluates its long-lived assets for impairment by continually
monitoring events and changes in circumstances that could indicate
carrying amounts of its long-lived assets may not be recoverable.
When such events or changes in circumstances occur, the Company
assesses recoverability by determining whether the carrying value
of such assets will be recovered through the undiscounted expected
future cash flows. If the expected undiscounted future cash flows
are less than the carrying amount of these assets, the Company then
measures the amount of the impairment loss based on the excess of
the carrying amount over the fair value of the assets. The Company
did not recognize impairment charges related to its long-lived
assets during the three and six months ended June&amp;#xA0;30, 2013,
and 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Foreign Currency
Remeasurement&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The functional
currency of the Company&amp;#x2019;s foreign subsidiary is the United
States dollar. Monetary assets and liabilities denominated in
foreign currencies are remeasured in United States dollars using
the exchange rates at the balance sheet date. Non-monetary assets
and liabilities denominated in foreign currencies are remeasured in
United States dollars using historical exchange rates. Revenues and
expenses are remeasured using average exchange rates prevailing
during the period. Remeasurements are recorded in the
Company&amp;#x2019;s condensed consolidated statements of operations.
The Company recorded foreign currency gains (losses) of $(0.2)
million and $(0.6) million during the three months ended
June&amp;#xA0;30, 2013, and 2012, respectively, and $(0.2) million
during each of the six months ended June&amp;#xA0;30, 2013, and
2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
accounts for stock-based compensation in accordance with ASC Topic
718, &lt;i&gt;&amp;#x201C;Compensation &amp;#x2013; Stock Compensation.&amp;#x201D;&lt;/i&gt;
Stock-based compensation expense is measured at the grant-date
based on the fair value of the award and is recognized as expense
on a straight-line basis over the requisite service period, which
is the vesting period, and is adjusted for estimated forfeitures.
To the extent that stock options contain performance criteria for
vesting, stock-based compensation is recognized once the
performance criteria are probable of being achieved.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;For stock-based
awards issued to non-employees, the Company follows ASC Topic
505-50, &lt;i&gt;&amp;#x201C;Equity Based Payment to Non-Employees&amp;#x201D;&lt;/i&gt;
and considers the measurement date at which the fair value of the
stock-based award is measured to be the earlier of (i)&amp;#xA0;the
date at which a commitment for performance by the grantee to earn
the equity instrument is reached or (ii)&amp;#xA0;the date at which the
grantee performance is complete. The Company recognizes stock-based
compensation expense for the fair value of the vested portion of
the non-employee stock-based awards in its condensed consolidated
statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See Note 11 in
the Notes to Condensed Consolidated Financial Statements for
further information regarding the Company&amp;#x2019;s stock-based
compensation assumptions and expenses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Warrant
Liability&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In August 2009,
and November 2010, the Company issued warrants to purchase an
aggregate of 2.4&amp;#xA0;million and 3.7&amp;#xA0;million shares of common
stock, respectively. The material terms of the warrants were
identical under each issuance except for the exercise price, date
issued and expiration date. The Company classified the warrants as
a liability on its condensed consolidated balance sheets as the
warrants contain certain material terms which require the Company
(or its successor) to purchase the warrants for cash in an amount
equal to the value of the unexercised portion of the warrants (as
determined in accordance with the Black-Scholes option pricing
model) in connection with certain change of control transactions.
In addition, the Company may also be required to pay cash to a
warrant holder under certain circumstances if the Company is unable
to timely deliver the shares acquired upon warrant exercise to such
holder.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The fair value
of these outstanding warrants is calculated using the
binomial-lattice option-pricing model and is adjusted accordingly
at each reporting period. The binomial-lattice option-pricing model
requires that the Company uses significant assumptions and judgment
to determine appropriate inputs to the model. Some of the
assumptions that the Company relies on include the probability of a
change of control occurring, the volatility of the Company&amp;#x2019;s
stock over the life of the warrant and assumptions and inputs used
to value the warrants under the Black-Scholes model should a change
of control occur.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Changes
resulting from the revaluation of warrants to fair value are
recorded in &amp;#x201C;Revaluation of warrant liability&amp;#x201D; on the
condensed consolidated statements of operations. Upon the exercise
or modification to remove the provisions which require the warrants
to be treated as a liability, the fair value of the warrants will
be reclassified from a liability to stockholders&amp;#x2019; equity on
the Company&amp;#x2019;s condensed consolidated balance sheets and no
further adjustment to the fair value would be made in subsequent
periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See Note 10 in
the Notes to Condensed Consolidated Financial Statements for
further information regarding the Company&amp;#x2019;s valuation of
warrant liability.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
accounts for income taxes using an asset and liability approach in
accordance with ASC Topic 740 &lt;i&gt;&amp;#x201C;Accounting for Income
Taxes.&amp;#x201D;&lt;/i&gt; Under this method, deferred tax assets and
liabilities are determined based on differences between the
financial reporting and tax bases of assets and liabilities and are
measured using the enacted tax rates and laws that will be in
effect when the differences are expected to reverse. ASC Topic 740
requires derecognition of tax positions that do not have a greater
than 50% likelihood of being recognized upon review by a taxing
authority having full knowledge of all relevant information. Use of
a valuation allowance as described in ASC Topic 740 is not an
appropriate substitute for the derecognition of a tax position. The
Company did not have any recorded liabilities for unrecognized tax
benefits at June&amp;#xA0;30, 2013, or December&amp;#xA0;31, 2012. The
Company recognizes accrued interest and penalties related to
unrecognized tax benefits in its income tax expense. To date, the
Company has not recognized any interest and penalties in its
condensed consolidated statements of operations, nor has its
accrued for or made payments for interest and penalties. The
Company continues to carry a full valuation allowance on all of its
deferred tax assets. Although the Company believes it more likely
than not that a taxing authority would agree with its current tax
positions, there can be no assurance that the tax positions the
Company has taken will be substantiated by a taxing authority if
reviewed. The Company&amp;#x2019;s tax years 1998 through 2012 remain
subject to examination by the taxing jurisdictions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Net Loss Per Common
Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic income
(loss) per common share is computed by dividing net income (loss)
by the weighted average number of common shares outstanding for the
period. Diluted income (loss) per common share gives effect to all
potentially dilutive common shares outstanding for the period. The
potentially dilutive securities include stock options, employee
stock purchase plan rights, warrants and restricted stock units,
which are calculated using the treasury stock method, and
convertible preferred stock, which is calculated using the
if-converted method. Diluted income (loss) per common share also
gives effect to potential adjustments to the numerator for changes
resulting from the revaluation of warrants to fair value for the
period, even if the Company is in a net loss position if the effect
would result in more dilution.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Diluted loss
per common share used the same weighted average number of common
shares outstanding for the six months ended June&amp;#xA0;30, 2013, and
2012, as calculated for the basic loss per common share as the
inclusion of any potential dilutive securities would be
anti-dilutive. In addition, certain potential dilutive securities
were excluded from the dilution calculation for the three months
ended June&amp;#xA0;30, 2013 and 2012, as their inclusion would have
been anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
table sets forth the reconciliation of the numerator and
denominator used in the computation of basic and diluted net loss
per common share for the three and six months ended June&amp;#xA0;30,
2013, and 2012 (in thousands, except per share amounts):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three Months
Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Six Months
Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss used for basic
calculation&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(6,724&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(1,907&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(16,976&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,741&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effect of revaluation of
warrant liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(686&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(3,674&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Adjusted net loss used for
diluted calculation&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(7,410&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(5,581&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(16,976&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(10,741&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic weighted average
number of common shares outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;69,727&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;54,418&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64,756&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;53,753&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Effect of dilutive
potential common shares resulting from warrants&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;2,201&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;818&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Diluted weighted average
number of common shares outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;71,928&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;55,236&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;64,756&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;53,753&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Net loss per common
share:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Basic&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.04&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.26&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.20&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Diluted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.26&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(0.20&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The table below
presents common shares underlying stock options, convertible
preferred stock, employee stock purchase plan rights, warrants and
restricted stock units that are excluded from the calculation of
the weighted average number of common shares outstanding used for
the calculation of diluted net loss per common share. These are
excluded from the calculation due to their anti-dilutive effect for
the three and six months ended June&amp;#xA0;30, 2013, and 2012 (shares
in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
&lt;tr&gt;
&lt;td width="73%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;Six Months
Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Weighted average of
anti-dilutive common shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;10,633&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;9,165&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;16,123&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;14,828&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Guarantee and
Indemnification Arrangements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
recognizes the fair value for guarantee and indemnification
arrangements issued or modified by the Company after
December&amp;#xA0;31, 2002. In addition, the Company monitors the
conditions that are subject to the guarantees and indemnifications
in order to identify if a loss has occurred. If the Company
determines it is probable that a loss has occurred, then any such
estimable loss would be recognized under those guarantees and
indemnifications. Some of the agreements that the Company is a
party to contain provisions that indemnify the counter party from
damages and costs resulting from claims that the Company&amp;#x2019;s
technology infringes the intellectual property rights of a third
party or claims that the sale or use of the Company&amp;#x2019;s
products have caused personal injury or other damage or loss. The
Company has not received any such requests for indemnification
under these provisions and has not been required to make material
payments pursuant to these provisions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
generally provides for a one-year warranty on certain of its
INTERCEPT blood-safety products covering defects in materials and
workmanship. The Company accrues costs associated with warranty
obligations when claims become known and are estimable. During the
year ended December&amp;#xA0;31, 2012, the Company provided for
warranty obligations related to replacement costs for certain of
its products that the Company identified were defective or had the
potential of being defective. In connection with the warranty
obligations provided for in relation to certain of its products
during the year ended December&amp;#xA0;31, 2012, the Company filed a
warranty claim against Fresenius, which Fresenius accepted. As a
result, the Company recorded a current asset of $1.8 million on its
consolidated balance sheets as of December&amp;#xA0;31, 2012
representing the full amount of the warranty claim against
Fresenius as Fresenius will supply the Company with replacement
products or credit notes for those defective or potentially
defective products. The Company also wrote-down the value of
certain unsalable inventory of $1.7 million related to these
products as an offsetting warranty claim against Fresenius as of
December&amp;#xA0;31, 2012. As of June&amp;#xA0;30, 2013, the Company no
longer has a warranty claim against Fresenius and all unsalable
inventory has been returned to Fresenius. During the three months
ended March&amp;#xA0;31, 2013, the Company identified a separate
production defect related to unsold inventory. The Company&amp;#x2019;s
third party manufacturer has taken responsibility for the cost of
replacing such damaged goods, therefore, the Company has borne no
costs associated with these defects. Prior to these incidents,
there have been very few warranty costs incurred. As a result, the
Company did not accrue for any potential future warranty costs at
June&amp;#xA0;30, 2013. In addition, the Company believes that the
defective products and those that had the potential of being
defective identified during the three months ended March&amp;#xA0;31,
2013 and during the year ended December&amp;#xA0;31, 2012 are
isolated.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Fair Value of Financial
Instruments&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
applies the provisions of fair value relating to its financial
assets and liabilities. The carrying amounts of accounts
receivables, accounts payable, and other accrued liabilities
approximate their fair value due to the relative short-term
maturities. Based on the borrowing rates currently available to the
Company for loans with similar terms, the Company believes the fair
value of its debt approximates their carrying amounts. The Company
measures and records certain financial assets and liabilities at
fair value on a recurring basis, including its available-for-sale
securities and warrant liability. The Company classifies
instruments within Level 1 if quote prices are available in active
markets, which include its money market funds as the maturity of
money market funds are relatively short and the carrying amount is
a reasonable estimate of fair value. The Company classifies
instruments in Level 2 if the instruments are valued using
observable inputs to quoted market prices, benchmark yields,
reported trades, broker/dealer quotes or alternative pricing
sources with reasonable levels of price transparency. These
instruments include the Company&amp;#x2019;s available-for-sale
securities related to United States government agencies. The
available-for-sale securities are held by a custodian who obtains
investment prices from a third party pricing provider that uses
standard inputs to models which vary by asset class. The Company
classifies instruments in Level 3 if one or more significant inputs
or significant value drivers are unobservable, which include its
warrant liability. The Company assesses any transfers among fair
value measurement levels at the end of each reporting
period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;See Note 2 and
10 in the Notes to Condensed Consolidated Financial Statements for
further information regarding the Company&amp;#x2019;s valuation on
financial instruments.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;New Accounting
Pronouncements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;There have been
no new accounting pronouncements issued during the three and six
months ended June&amp;#xA0;30, 2013, that are of significance, or
potential significance, to the Company. Any recent accounting
pronouncement that are of significance, or potential significance,
to the Company are set forth in the Company&amp;#x2019;s Annual Report
on Form 10-K for the year ended December&amp;#xA0;31, 2012, filed with
the SEC on March&amp;#xA0;12, 2013, under Note 2 in the Notes to
Consolidated Financial Statements.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</NonNumbericText><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>nonnum:textBlockItemType</ElementDataType><SimpleDataType>na</SimpleDataType><ElementDefenition>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</ElementDefenition><ElementReferences>No definition available.</ElementReferences><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>Summary of Significant Accounting Policies</Label></Row></Rows><Footnotes /><IsEquityReport>false</IsEquityReport><ReportName>Summary of Significant Accounting Policies</ReportName><MonetaryRoundingLevel>UnKnown</MonetaryRoundingLevel><SharesRoundingLevel>UnKnown</SharesRoundingLevel><PerShareRoundingLevel>UnKnown</PerShareRoundingLevel><ExchangeRateRoundingLevel>UnKnown</ExchangeRateRoundingLevel><HasCustomUnits>true</HasCustomUnits><IsEmbedReport>false</IsEmbedReport><IsMultiCurrency>false</IsMultiCurrency><ReportType>Sheet</ReportType><RoleURI>http://www.cerus.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</RoleURI><NumberOfCols>1</NumberOfCols><NumberOfRows>1</NumberOfRows></InstanceReport>
